Protagonist Therapeutics, Inc.
PTGX
$103.88
$3.933.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -64.36% | -89.41% | -35.39% | -34.45% | -34.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -64.36% | -89.41% | -35.39% | -34.45% | -34.02% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -64.36% | -89.41% | -35.39% | -34.45% | -34.02% |
| SG&A Expenses | 15.15% | 3.20% | -0.44% | 3.34% | 1.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.91% | 12.42% | 8.89% | 10.98% | 8.60% |
| Operating Income | -623.31% | -162.54% | -87.25% | -84.25% | -81.69% |
| Income Before Tax | -302.10% | -146.28% | -72.23% | -68.84% | -65.49% |
| Income Tax Expenses | -174.27% | -80.14% | -3.05% | -34.26% | -73.12% |
| Earnings from Continuing Operations | -304.14% | -147.29% | -73.13% | -69.38% | -65.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -304.14% | -147.29% | -73.13% | -69.38% | -65.34% |
| EBIT | -623.31% | -162.54% | -87.25% | -84.25% | -81.69% |
| EBITDA | -602.68% | -161.83% | -86.65% | -83.77% | -81.25% |
| EPS Basic | -302.10% | -145.57% | -72.97% | -69.75% | -65.83% |
| Normalized Basic EPS | -300.05% | -144.59% | -72.10% | -69.23% | -66.01% |
| EPS Diluted | -340.73% | -148.94% | -76.49% | -73.08% | -69.04% |
| Normalized Diluted EPS | -334.49% | -147.53% | -75.33% | -72.33% | -69.10% |
| Average Basic Shares Outstanding | 3.24% | 3.26% | 3.38% | 3.66% | 4.71% |
| Average Diluted Shares Outstanding | 3.71% | 0.48% | 3.30% | 3.57% | 4.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |